newsfilter
← Latest News
GlobeNewswire·

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA,